177 related articles for article (PubMed ID: 1171804)
1. Antigenicity of "monocomponent" pork insulin in diabetic subjects.
Yue DK; Turtle JR
Diabetes; 1975 Jul; 24(7):625-32. PubMed ID: 1171804
[TBL] [Abstract][Full Text] [Related]
2. [The antigenicity of various new chromatographically purified depot insulin preparations].
Graber D; Fankhauser S
Schweiz Med Wochenschr; 1978 Nov; 108(46):1807-9. PubMed ID: 715418
[TBL] [Abstract][Full Text] [Related]
3. The production and characteristics of anti-insulin, anti-A-component and anti-proinsulin antibodies in patients treated with monocomponent or conventional insulin.
Kawazu S; Kanazawa Y; Miki E; Hayashi M; Sando H; Kajinuma H; Iwamoto Y; Akanuma Y; Kosaka K
Acta Diabetol Lat; 1979; 16(4):339-51. PubMed ID: 399151
[TBL] [Abstract][Full Text] [Related]
4. Controlled study comparing treatment with monocomponent insulin and conventional insulin in patients with lipoatrophy.
Czyzyk A; Rogala H; Lawecki J
Acta Diabetol Lat; 1989; 26(1):17-26. PubMed ID: 2665407
[TBL] [Abstract][Full Text] [Related]
5. Clinical aspects of monocomponent insulins in the treatment of diabetes.
Vinik AI; Joffe BI; Seftel HC; Distiller LA; Jackson WP
S Afr Med J; 1976 Apr; 50(15):587-91. PubMed ID: 1265555
[TBL] [Abstract][Full Text] [Related]
6. Circulating antibodies in diabetics treated with conventional and purified insulins.
Klaff LJ; Vinik AI; Berelowitz M; Jackson WP
S Afr Med J; 1978 Jul; 54(4):149-53. PubMed ID: 694712
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals.
Schernthaner G; Borkenstein M; Fink M; Mayr WR; Menzel J; Schober E
Diabetes Care; 1983; 6 Suppl 1():43-8. PubMed ID: 6343038
[TBL] [Abstract][Full Text] [Related]
8. Proinsulin and A-component antibodies in diabetics after long-term monocomponent insulin treatment.
Bruni B; Gamba S; Regis G; Turco GL
Diabetologia; 1978 Mar; 14(3):165-9. PubMed ID: 566232
[TBL] [Abstract][Full Text] [Related]
9. [Purity and antigenicity of the new insulin preparations].
Fankhauser S
Schweiz Med Wochenschr; 1976 Sep; 106(36):1218-25. PubMed ID: 996531
[TBL] [Abstract][Full Text] [Related]
10. Transfer from purified porcine insulins to semisynthetic human insulins decreases insulin antibodies and circulating immune complexes in diabetic children and adolescents. A two-year follow-up.
Dorchy H; Duchateau J; Bosson D; D'Hooge D
Diabete Metab; 1989; 15(3):107-10. PubMed ID: 2668052
[TBL] [Abstract][Full Text] [Related]
11. [Experiences in the treatment of diabetes with insulins of monocomponent (MC) and monospecies (MS) type].
Andreani D; Iavicoli M; Colletti A; Menzinger G
Folia Endocrinol; 1972 Dec; 25(6):516-39. PubMed ID: 4581824
[No Abstract] [Full Text] [Related]
12. Antibody formation and insulin requirements in diabetic children during treatment with purified commercial pork insulins.
Weber B; Tech J; Schmidt H; Oberdisse U
Eur J Pediatr; 1978 Jun; 128(2):89-102. PubMed ID: 566669
[TBL] [Abstract][Full Text] [Related]
13. Letter: Antigenicity of "monocomponent" insulins.
Yue DK; Turtle JR
Lancet; 1974 Oct; 2(7887):1022. PubMed ID: 4138266
[No Abstract] [Full Text] [Related]
14. [Proinsulin and a-component antibodies in diabetics treated with monocomponent and conventional insulin].
Gamba S; Barbero PL; Bollati C; Castellazzi R; D'Adda A; Bruni B
Minerva Dietol Gastroenterol; 1979; 25(3):309-14. PubMed ID: 400003
[No Abstract] [Full Text] [Related]
15. Decrease of antibodies to insulin, proinsulin and contaminating hormones after changing treatment from conventional beef to purified pork insulin.
Kurtz AB; Matthews JA; Mustaffa BE; Daggett PR; Nabarro JD
Diabetologia; 1980; 18(2):147-50. PubMed ID: 6988274
[TBL] [Abstract][Full Text] [Related]
16. [Clinical experiences with monocomponent insulins].
Bruni Bocher K; Giolitti A; Turco GL; Benedetto P; Bruni B
Minerva Med; 1975 Mar; 66(19):909-30. PubMed ID: 1124144
[TBL] [Abstract][Full Text] [Related]
17. Reduction in insulin antibodies 42 months after transfer from porcine to human monocomponent insulins.
Virgili F; Frigato F; Magnanini PG; Coronel GA; Iavicoli M
Diabetes Res; 1988 Sep; 9(1):19-20. PubMed ID: 3071441
[TBL] [Abstract][Full Text] [Related]
18. Effects of new insulins on insulin and C-peptide antibodies, insulin dose, and diabetic control.
Peacock I; Tattersall RB; Taylor A; Douglas CA; Reeves WG
Lancet; 1983 Jan; 1(8317):149-52. PubMed ID: 6130198
[TBL] [Abstract][Full Text] [Related]
19. [The preparation of highly purified insulin and its clinical use. Insulin Cooperative Study Group].
Yang J; Fang F; Zhu X; Deng S; Zhou W; Xing Z
Hua Xi Yi Ke Da Xue Xue Bao; 1991 Jun; 22(2):178-80. PubMed ID: 1786955
[TBL] [Abstract][Full Text] [Related]
20. The human cellular immune response to insulin: a study in unexposed control subjects and type I diabetic patients on acute and chronic treatment.
Richens ER; Seward ME; Luqman WA; Hartog M
Acta Diabetol Lat; 1986; 23(4):309-22. PubMed ID: 3551427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
